Transthyretin Amyloid Cardiomyopathy Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
See the next evidence inflection points before they arrive. This readout-outlook report connects Clinical Trials, Drug & Asset, and Company & Deal Intelligence data through PatSnap MCP Servers. Explore the PatSnap MCP Marketplace to monitor the same endpoint, sponsor and timing signals inside your own AI workflow.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. This is strategic research, not medical advice. Trial status, endpoints and timing can change; confirm the underlying records before making decisions.
Readout outlook: why this landscape matters now
Transthyretin Amyloid Cardiomyopathy remains an active clinical development field. Development is moving beyond single surrogate measures toward integrated cardiometabolic, renal and clinical-outcome evidence, with convenience and persistence becoming major differentiators. The PatSnap evidence set used here contains 102 matched trial records and 76 indexed result records before the decision-focused sample below was selected. This companion outlook shifts the decision lens from market breadth to evidence timing: which endpoints can change practice, which sponsors can execute across geographies, and where the next readout may still leave uncertainty.
MCP workflow for a readout-focused landscape
The analysis starts with Clinical Trials MCP and clinical_trial_fetch to align phase, recruitment status, sponsor, countries, primary endpoints and completion dates. clinical_trial_result_fetch then separates already indexed evidence from future catalysts. Drug & Asset drug_fetch adds mechanism and global development status; Company & Deal Intelligence organization_fetch adds sponsor context. Use PatSnap MCP Servers to keep each layer traceable instead of inferring asset or company facts from trial titles.
Trial, endpoint and expected-readout map
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| ChiCTR2600127950 | Intervention not normalized | Not Applicable; Not yet recruiting | Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences | China | Area under ROC curve of 99Tcm-PYP imaging for ATTR-CA diagnosis (After 99Tcm-PYP SPECT(/CT) scan, matched with pathological, genetic and…) | 2027-12-31 |
| NCT07695701 | Acoramidis | Phase 4; Not yet recruiting | Eidos Therapeutics, Inc. | Geography not listed | To assess the effect of acoramidis on cardiac function improvement by CMR in participants with ATTR-CM. (Month 36) | 2030-08-01 |
| NCT07690436 | Intervention not normalized | Not Applicable; Not yet recruiting | AstraZeneca PLC | United States, Portugal, Germany, Spain | Comparison of per-participant confidence scores distributions between ATTR-CM cases and HF controls without ATTR-CM (At a single assessment time point within 90 days following informed consent…); Qualitative assessment of features learned indicative of ATTR pathology (At a single assessment time point within 90 days following informed consent…) | 2027-06-03 |
| NCT07689331 | Intervention not normalized | Not Applicable; Recruiting | Semmelweis University | Hungary | Sex of Participants at Diagnosis (Baseline); Age at Diagnosis (Baseline) | 2028-05-01 |
Read the table horizontally. Phase shows nominal maturity, but endpoint choice shows what the study can actually prove; geography signals operational breadth; and expected timing reveals whether a program is a near-term catalyst or a long-duration strategic bet.
Readout signals already on record
- Vutrisiran in East Asian Patients With Transthyretin Amyloidosis With Cardiomyopathy (Phase 3): the indexed record reports Composite endpoint(all-cause mortality and recurrent cardiovascular events): HR = 0.2(95.0% CI, 0.04 - 0.93); Composite endpoint(all-cause mortality and recurrent cardiovascular events): HR = 0.2(95.0% CI, 0.04 - 0.93).
- Long-Term Efficacy of Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy by National Amyloidosis Centre stage (Phase 3): the indexed record reports CV-related mortality = 74 %; CV-related mortality = 55 %.
- HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) (Phase 3): the indexed record reports Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular (CV) Events (CV Hospitalizations and Urgent Heart Failure [HF] Visits) in the Overall Population = 125 Participants; Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular (CV) Events (CV Hospitalizations and Urgent Heart Failure [HF] Visits) in the Overall Population = 159 Participants; Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular (CV) Events (CV Hospitalizations and Urgent Heart Failure [HF] Visits) in the Overall Population: Hazard Ratio (HR) = 0.718(95% CI, 0.555 - 0.929), P-Value = 0.0118.
These signals are anchors, not league tables. Differences in population, prior treatment, baseline risk, estimand, endpoint definition and follow-up can overwhelm apparent numerical comparisons. The useful question is which uncertainty each result resolves before the next catalyst.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
How assets and sponsors shape readout probability
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Acoramidis (Approved; TTR). Company & Deal Intelligence records identify sponsor context for Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences, Eidos Therapeutics, Inc. (EIDX), AstraZeneca PLC (AZN), Semmelweis University. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Evidence white space before the next readout cycle
- Active-comparator trials on top of contemporary standard of care.
- Hard cardiovascular, kidney or liver outcomes linked to earlier biomarker change.
- Evidence in underrepresented populations and patients with multiple comorbidities.
- Durability, adherence and post-discontinuation outcomes.
Readout-risk implications
A crowded field does not guarantee a crowded evidence set. Programs can still differentiate through an active comparator, a clinically meaningful endpoint, a biomarker-defined responder group, broader geography, or a credible sequencing plan. Sponsors should pressure-test whether the planned readout will close a decision gap; BD teams should distinguish mechanism novelty from evidence novelty; investors should track endpoint maturity and execution risk alongside phase.
Readout watchlist
Monitor recruitment changes, protocol amendments, primary-completion dates, new result indexing, sponsor ownership and multinational expansion. Re-run the MCP workflow as a delta analysis. A change from surrogate to clinical outcome, a delayed completion date, a new active comparator or a scaled partner can materially alter the probability and strategic meaning of the next readout.
Bottom line
Transthyretin Amyloid Cardiomyopathy has multiple clinical catalysts, but their value depends on endpoint quality, execution and context. A readout outlook is most useful when it joins trial design, indexed results, asset mechanism and sponsor capacity in one traceable view.
Build your own readout monitor: Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable components for catalyst tracking and SEO-ready reports.
